Piper Sandler analyst David Amsellem initiates coverage on Definium Therapeutics Inc (NASDAQ: DFTX) with a Overweight rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage